Behavioral and electrophysiological abnormalities in two rat models of antiretroviral drug-induced neuropathy.
Painful peripheral neuropathy due to the antiretroviral therapy used to treat HIV is one of the most prevalent side effects occurring in at least 30% of patients living with this infection. We have evaluated the electrophysiological and behavioral effects of d4T and ddC on peripheral large and small nerve fibers in male rats treated with d4T (Sprague-Dawley, 50 mg/kg, twice within 1 week), ddC (Wistar, 50 mg/kg, 3 times per week for 3 weeks), or vehicle. The effect of the interventions was assessed using behavioral measures of mechanical sensitivity, conventional nerve conduction studies, and microneurographic single nerve C-fiber recordings. To mimic as much as possible the human clinical condition, all treated animals were included in the study. No statistically significant differences were observed in behavioral parameters of mechanical sensitivity. Nerve conduction studies did not reveal any significant change in the ddC-treated group. In contrast, we observed electrophysiological evidence of significant demyelinating neuropathy 1 week after the start of d4T treatment. Additionally, spontaneous activity in mechanoinsensitive C-nociceptors was observed in both drug-treated groups. No relationship could be established between measures of spontaneous activity in C-nociceptors and the results of the behavioral tests. Our results show that both models of antiretroviral-induced neuropathy differ in their effects on peripheral nerves. However, both groups present abnormal spontaneous activity in mechanoinsensitive C-nociceptors that can be used as a model for pharmacological intervention.
Neuroscience Technologies, Parc Científic de Barcelona, Barcelona, Spain.
Elizabeth
E
Garcia-Perez
Romà
R
Solà
Mireia
M
Sumalla
Jordi
J
Serra
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D019380:Anti-HIV Agents / Q000633:toxicity*; D004195:Disease Models, Animal; D008297:Male; D036421:Nerve Fibers, Unmyelinated / Q000502:physiology; D009431:Neural Conduction / Q000187:drug effects*; D009482:Neurophysiology; D010147:Pain Measurement; D017288:Pain Threshold / Q000187:drug effects*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000150:complications*; D010812:Physical Stimulation; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D018119:Stavudine / Q000633:toxicity; D016047:Zalcitabine / Q000633:toxicity
D019380:Anti-HIV Agents; D016047:Zalcitabine; D018119:Stavudine